Fri, 15 Jan 2021 15:03:21: | Landos Biopharma guns for a $100M IPO to boost AI autoimmune R&D work
|
Fri, 15 Jan 2021 13:15:26: | How a gene linked to the circadian clock could point to new prostate cancer treatments
|
Fri, 15 Jan 2021 12:51:41: | NextCure nabs NexImmune, Celgene research vet as new CMO 6 months after former CMO quit
|
Fri, 15 Jan 2021 12:49:59: | Sinopharm claims COVID-19 vaccine safe in kids aged 3 and up
|
Fri, 15 Jan 2021 10:49:34: | Ex-Merck scientist accused of stealing trade secrets on Keytruda, raising threat of 10-year prison term
|
Fri, 15 Jan 2021 06:15:19: | Chutes & Ladders—Bristol Myers hematology chief Ahmed hits exit
|
Thu, 14 Jan 2021 14:27:57: | Meet Binney Street Capital: Dana-Farber Cancer Institute's first venture fund
|
Thu, 14 Jan 2021 14:06:44: | Knopp's oral asthma drug hits primary endpoint in phase 2
|
Thu, 14 Jan 2021 13:23:31: | NewAmsterdam bags $196M to resurrect Amgen's discarded CETP drug
|
Thu, 14 Jan 2021 10:34:31: | Eye stem cell transplant to treat blindness bolsters retinal function in monkeys
|
Thu, 14 Jan 2021 08:52:11: | Secretive Sana, still a year away from the clinic, files for an IPO after a mammoth raise
|
Wed, 13 Jan 2021 14:40:01: | JPM, Day 3: CureVac partner Bayer says not to discount its vaccine efforts, CROs better prepped for new wave and more
|
Wed, 13 Jan 2021 14:16:00: | JPM: CureVac's new pharma partner Bayer says its COVID-19 vaccine not just an also-ran
|
Wed, 13 Jan 2021 13:25:54: | Evoq pens $240M Amgen pact for next-gen autoimmune meds
|
Wed, 13 Jan 2021 12:10:34: | A COVID-19 treatment candidate that fuses tiny antibodies from llamas and alpacas shows promise
|
Wed, 13 Jan 2021 11:25:03: | Celltrion's COVID-19 antibody improves outcomes in phase 2
|
Wed, 13 Jan 2021 10:45:02: | IO Biotech raises $155M to trial IDO and PD-L1 cancer vaccines
|
Wed, 13 Jan 2021 09:39:34: | JPM: PPD C-suite says CROs 'better prepared' as COVID-19 surges, sees pandemic trials a long-term opportunity
|
Tue, 12 Jan 2021 18:20:30: | Major hep B players Gilead and Vir join forces to find a cure
|
Tue, 12 Jan 2021 13:38:13: | JPM, Day 2: Sanofi continues deal spree, Boehringer shines light on dark antigens and more
|
Tue, 12 Jan 2021 13:36:08: | Pfizer invests $120M in 4 biotechs through new growth fund
|
Tue, 12 Jan 2021 09:51:03: | JPM: Sanofi pays $125M to take lead in new checkpoint inhibitor space
|
Tue, 12 Jan 2021 09:43:33: | JPM: Novartis CMO Tsai on how the pandemic is changing the face of biopharma R&D, how pharma works
|
Tue, 12 Jan 2021 09:03:46: | JPM: Boehringer inks Enara deal to source 'dark antigens' for cancer immunotherapies
|
Tue, 12 Jan 2021 03:36:41: | JPM: Verve Therapeutics unveils its lead program—a one-and-done treatment for genetic high cholesterol
|